Understanding how blood flow and pressure affect lungs in PAH

Who could benefit from this research

What this research studies

This project uses bioengineering tools to study how shear stress and pressure in the lung arteries influence PAH in people who have the condition. It builds on data showing PAH patients’ arterial cells respond differently to high shear forces, and it plans to connect those responses to individual patient factors. The work combines vascular biology with innovative microfluidic models to mimic lung blood flow and examine cellular signaling related to calcium and cell communication. The goal is to identify pathways that could be targeted to prevent or slow PAH progression. Participation would involve analyzing patient-derived cells and potentially future therapeutic studies.

Why it matters

Where this research is happening

• University of Washington
  Seattle, United States Active

Researchers

• Principal investigator: Rayner, Samuel Gibson — University of Washington
• Study coordinator: Rayner, Samuel Gibson

Related research

Other NIH-funded projects on the same topics.

• Asporin as a double-targeted therapy and biomarker for a serious artery disease

  This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11450594

• Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease

  A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11419895

• A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension

  A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11418121

• Endothelial inflammation and Src kinase in early pulmonary arterial hypertension

  Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.

  NIH research Brigham and Women's Hospital · Boston, United States · NIH-11411210

• Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs

  A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.

  NIH research Medluidics LLC · Elk Grove, United States · NIH-11410451

• Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

  A 3-center, placebo-controlled study tests whether daily 10 mg empagliflozin for 24 weeks can help heart function and other outcomes in people with PAH.

  NIH research Cleveland Clinic Lerner Com-Cwru · Cleveland, United States · NIH-11399092

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.